Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
new york blog main
3
×
new york top stories
biotech
cancer
investing
national top stories
new york
pfizer
san diego blog main
san diego top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
agios pharmaceuticals
akcea therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amarin
amgen
anylam pharmaceuticals
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
axitinib
bellus health
biotech ipos
bolt biotherapeutics
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
cancer drugs
What
sets
3
×
drug
medicines
patients
advantages
ago
akcea
alnylam
amyloidosis
approved
attr
available
bar
battle
bio
brings
company’s
course
debilitating
development
discover
disease
expect
experimental
fda
gamble
genetic
growing
handiwork
helped
internal
ipo
landscape
market
medco’s
mover
new
oks
payers
pfizer
Language
unset
Current search:
sets
×
" new york blog main "
×
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea